Us Generics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Us generics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Us Generics Today - Breaking & Trending Today

New capacities to help hospitals outpace pharma in FY25

While hospital chains are expanding capacity at a healthy rate, key growth drivers of pharma companies are showing signs of moderation ....

Revenue Growth , Capacity Expansion , Us Generics , New Product Launches ,

What's after Revlimid for Dr Reddy's, Cipla, and Sun Pharma?

The patent on Revlimid expires in January 2026 and the three pharma majors, which have seen strong growth on the back of this drug, are looking for other opportunities to keep their growth path. They appear to have aces up their sleeves. ....

Sun Pharma , Aurobindo Pharma , Dr Reddy Labs , Elara Capital , Concert Pharma , Dr Reddy S , Sun Pharma , Indian Pharma , Indian Pharmaceutical , Us Generics ,

Pharma Q2 growth in India slows, hopes hinge on US

Growth in the Indian pharma market slowed to 7 percent in Q2 of FY24 from 8.5 percent in Q1 ....

Q2 Fy24 , India Pharma Market , Us Generics , Product Launches , Pricing Environment ,

Dr Reddy's Q1: Just an overdose of Revlimid, not much growth ahead, say brokerages

Even though the company’s profit, revenue and profitability exceeded expectations, brokerages feel that the growth in recent quarters was fuelled by the spectacular sales of Revlimid. They say the contribution from the drug will soon start waning out, and many still retain their ‘hold’ and ‘sell’ calls. ....

Dr Reddys Laboratories , Us Generics , R Reddys Q1 , R Reddys Q1 Quarterly Results , R Reddys Q1 Earnings , Brokerage Views ,

Why is Indian pharma failing to meet US standards?

It’s not as if domestic manufacturing has suddenly become sloppy. A closer look will reveal the strides made by Indian pharma firms as they attempt to break into the complex drugs space, which attracts higher scrutiny. ....

Sun Pharma Mohali , Drug Administration , Vineet Gala , Xylem Investment Managers , Sun Pharma , Ipca Laboratories , Sun Pharmaceutical Industries , Us Generics , Pharma Sector ,